ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Nov 10, 2016
Assessing Reactions to Trump’s Victory
Image Source: Gage Skidmore. Donald Trump will be the 45th President of the United States of America. Let’s dig into some of the reactions across the market. We’re keeping our cool.
Nov 2, 2016
Earnings Insight – Gilead Sciences
Image Source: Gilead. Let’s cover some ground on Gilead Sciences third-quarter report.
Oct 15, 2016
Video: An Overview of Our 16-page Stock Research Reports
President of Equity Research, Brian Nelson, walks through how financial advisors and individual investors can get the most out of Valuentum's 16-page equity report.
Oct 14, 2016
Where I Went Wrong on Gilead
Image Source: torbakhopper. Let’s walk through our run-in with Gilead.
Oct 13, 2016
Understanding the Chartered Financial Analyst (CFA) Designation
Let's examine why the Economist (magazine) calls the CFA the gold standard in the investment industry.
Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late.
Jul 27, 2016
Gilead’s Harvoni Sales Dip Considerably in the US
Image Source: Gilead. The bull case for owning Gilead has become bleak.
May 17, 2016
Big Pharma 1Q Earnings Roundup, Part II
Image Source: Paw Paw. Let’s take a look at the first quarter performance and some major news for some of the biggest players in the pharmaceuticals sector. Included in this article: ABBV, AGN, BMY, AMGN, MRK, PFE.
May 2, 2016
Gilead: What's Your Long Term Thesis?
Image Source: Gilead. We’re starting to see some even bigger risks at Gilead – long-term ones.
Apr 29, 2016
Gilead Disappoints, Harvoni Sales Drop 16%
Image Source: Gilead. In January 2016, we had removed Gilead from the Best Ideas Newsletter portfolio, and we added steady-eddy dividend growth giant Johnson & Johnson in its place. We were starting to think we might have made a mistake … until today.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.